AlphaGene identifies prostate cancer marker:
This article was originally published in Clinica
Executive Summary
AlphaGene has discovered a potential new marker for prostate cancer, which it claims may provide a more reliable test for the disease than the widely used prostate specific antigen marker. The new marker is a member of the human carcinoembryonic antigen (CEA) subgroup. Other CEA subgroup members are already used as biomarkers for colon cancer, says the Woburn, Massachusetts firm. AlphaGene is seeking partners for a co-operative research and development project using its marker.